Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562135 | 1.00 | ADORA3 (0.59) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL17193423 | 0.94 | ADORA3 (0.55) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL1375404 | 0.94 | ADORA3 (0.55) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL25400020 | 0.94 | ADORA3 (0.55) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL1375398 | 0.94 | ADORA3 (0.55) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL12851722 | 0.88 | ADORA3 (0.53) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL14946268 | 0.87 | ADORA3 (0.59) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL14853765 | 0.87 | ADORA3 (0.59) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL17471689 | 0.87 | ADORA3 (0.59) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL3437123 | 0.87 | ADORA3 (0.59) | ADORA3HINT1NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-116368146-A | Novel ligands for asialoglycoprotein receptors | 赛诺菲 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022084331-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI (FR) | 2022-04-28 | — | — | WO | disclosed |
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | ROCHE PALO ALTO LLC (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | ROCHE PALO ALTO LLC (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | ROCHE PALO ALTO LLC (US) | 2013-09-12 | — | — | US | disclosed |
| US-7915232-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915232-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT | 2010-01-07 | — | — | US | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-6784166-B2 | FOR THE TREATMENT OF DISEASES MEDIATED BY THE HEPATITIS C VIRUS | SYNTEX (U.S.A.) LLC | 2004-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | ADORA3 583/4885HINT1 662/4885NT5E 399/4885 |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | NSUN2, RNGTT, RNMT | ADORA3 583/4885HINT1 662/4885NT5E 399/4885 |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | ADORA3 583/4885HINT1 662/4885NT5E 399/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | ADORA3 68/4885HINT1 846/4885NT5E 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.